Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaJAMA Oncol 2021 Oct 21;[EPub Ahead of Print], L Hirsch, N Martinez Chanza, S Farah, W Xie, R Flippot, DA Braun, N Rathi, J Thouvenin, KA Collier, E Seront, G de Velasco, H Dzimitrowicz, B Beuselinck, W Xu, IA Bowman, ET Lam, B Abuqayas, MA Bilen, A Varkaris, Y Zakharia, MR Harrison, A Mortazavi, P Barthélémy, N Agarwal, RR McKay, PK Brastianos, KM Krajewski, L Albigès, LC Harshman, TK Choueiri
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.